Irvine-based Visiogen Inc., an innovative developer of products for cataract and refractive patients, announced Monday that it has raised $40 million from new and current investors to support the global commercialization of its Synchrony product.
Lead investor Novartis Venture Fund, along with Technology Partners, made major contributions to this round of financing, which was also strongly supported by current investors Three Arch Partners, New Leaf Venture Partners, Prospect Venture Partners, CMEA Ventures and Foundation Medical Partners.
Synchrony is a dual-optic accommodating intraocular lens (IOL), which is intended for use in cataract and refractive patients. Since its last round of financing in 2007, Visiogen has made significant progress in the development of Synchrony IOL, including the completion of the U.S. phase III study.
NEXT PAGE >>
Kaiser Permanente Orange County tops agency in breast cancer screenings
Komen O.C. receives 10K donation, announces board
Tustin's Peregrine Pharmaceuticals sees promising results
Orange County law enforcement officials take part in weight-loss program
'OC METRO Minute,' April 22: Hoag Hospital ranks in top 125 hospitals